Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTA), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. reports news centered on PAS-004, its next-generation macrocyclic MEK inhibitor, and the company’s clinical-stage biotechnology operations. Recurring updates cover NF1-associated plexiform and cutaneous neurofibromas, advanced cancer, ALS-related research, FDA designations, clinical development strategy and medical leadership.
Company news also includes capital actions, investor conference presentations and public-company matters tied to common stock and warrant securities. Pasithea’s releases frame the business around drug-development progress, regulatory designations and financing activity supporting research, preclinical work and clinical trials.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced that CEO Dr. Tiago Reis Marques will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 10:10 AM ET. The live presentation will be available via webcast and archived for 30 days on the company's website. Pasithea focuses on developing treatments for psychiatric and neurological disorders, targeting pathophysiology to improve efficacy and tolerability compared to conventional therapies. The company also provides business support services for anti-depression clinics in the UK and the US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has successfully closed its initial public offering of 4,800,000 units at a price of $5.00 per unit, generating approximately $24.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant for an additional share. The company's stock and warrants began trading on Nasdaq on September 15, 2021. The offering aims to support the company’s focus on discovering new treatments for psychiatric and neurological disorders.